Bioford Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 14 Year, 24 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 551452.93%
(FY 2023)
- Profit 43132.90%
(FY 2023)
- Ebitda 46443.29%
(FY 2023)
- Net Worth 4065.53%
(FY 2023)
- Total Assets 30909.22%
(FY 2023)
About Bioford Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sunil Goel and Vikas Goel serve as directors at the Company.
- CIN/LLPIN
U24100DL2010PTC210762
- Company No.
210762
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bioford Remedies Private Limited offer?
Bioford Remedies Private Limited offers a wide range of products and services, including Vitamins & Supplements, Mineral Supplements.
Who are the key members and board of directors at Bioford Remedies?
Board Members(2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sunil Goel | Director | 20-Aug-2011 | Current |
Vikas Goel | Director | 25-Nov-2010 | Current |
Financial Performance and Corporate Structure Insights of Bioford Remedies.
Bioford Remedies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 551452.93% increase. The company also saw a substantial improvement in profitability, with a 43132.9% increase in profit. The company's net worth Soared by an impressive increase of 4065.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Bioford Remedies?
In 2023, Bioford Remedies had a promoter holding of 80.00% and a public holding of 20.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Knoll Healthcare Private LimitedActive 16 years 7 months
Sunil Goel and Vikas Goel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioford Remedies?
Unlock and access historical data on people associated with Bioford Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioford Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioford Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.